证券代码：688117 证券简称：圣诺生物 公告编号：2026-003 成都圣诺生物科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以成都圣诺生物 科技股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：人民币元 ■ 3、影响经营业绩的主要因素 报告期内，公司持续专注于主营业务多肽药物CDMO、原料药和制剂的协同发展，得益于全球多肽药物 市场降糖、减重领域的药品需求持续放量，使得公司GLP-1原料药销量大增，经营业绩大幅提升。 （二）上表中有关项目增减变动幅度达30%以上的主要原因 注：1.本报告期初数同法定披露的上年年末数。 2.表中财务数据及指标均以合并报表数据填列，但未经审计，最终结果以公司2025年年度报告为准；表 中增减变动幅度数据如有尾差，系四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状 ...

报告期内，公司持续专注于主营业务多肽药物CDMO、原料药和制剂的协同发展，得益于全球多肽药物 市场降糖、减重领域的药品需求持续放量，使得公司GLP-1原料药销量大增，经营业绩大幅提升。 格隆汇2月27日丨圣诺生物(688117.SH)公布2025年度业绩快报，2025年度公司实现营业收入7.41亿元， 较上年同期增长62.55%；实现归属于母公司所有者的净利润1.66亿元，较上年同期增长231.49%；实现 归属于母公司所有者的扣除非经常性损益的净利润1.73亿元，较上年同期增长278.52%。 ...

来源：市场资讯 （来源：弗若斯特沙利文） 2026年2月13日，普莱医药-B首次向港交所递交招股书，拟在香港主板上市，独家保荐人为中信。 公司是一家领先创新型抗菌肽（「AMP」）治疗药物公司，2024年收入0.05亿元，净亏损1.58亿元。 2025年前9月收入0.03亿元，净亏损1.01亿元。 公司是一家于2009年4月成立的领先创新型抗菌肽（「AMP」）治疗药物公司，秉持「以科技创新服务 人类健康」的理念。公司专注于四个核心治疗领域，即抗感染、代谢疾病、肿瘤及自身免疫疾病，致力 于透过公司的专有突破性技术及候选药物解决全球重大未被满足的健康需求。 截至最后实际可行日期，公司有九种候选药物，包括一种核心产品（即PL-5）及两种主要产品（即PL- 3301及PL-18）。 涵盖感染性疾病、代谢性疾病、肿瘤及自身免疫性疾病。该等候选药物的目标适应症包括继发性创面感 染、糖尿病足感染（「DFI」）、外阴阴道念珠菌病（「VVC」）、口咽念珠菌病（「OPC」）、肺部 感染、全身感染、肥胖症、代谢功能障碍相关脂肪性肝炎（「MASH」）、溃疡性结肠炎 （「UC」）、实体瘤、血液肿瘤，及其他自身免疫性疾病。 根据弗若斯特沙 ...

智通财经APP获悉，据港交所2月13日披露，普莱医药(江苏)股份有限公司(简称：普莱医药)向港交所主 板递交上市申请，中信证券为其独家保荐人。公司核心产品PL-5于2024年在中国进入监管申报阶段，已 向国家药品监督管理局药品审评中心提交新药上市申请。 毛利 公司简介 招股书显示，普莱医药是一家于2009年4月成立的领先创新型抗菌肽(AMP)治疗药物公司，专注于四个 核心治疗领域，即抗感染、代谢疾病、肿瘤及自身免疫疾病，致力于通过公司的专有突破性技术及候选 药物解决全球重大未被满足的健康需求。截至最后实际可行日期，普莱医药有九种候选药物，包括一种 核心产品(即PL-5)及两种主要产品(即PL-3301及PL-18)。 根据弗若斯特沙利文的数据，公司的核心产品PL-5(培来加南)是首款已在全球提交新药上市申请(NDA) 的加南类药物。凭借创始人于2006年首次共同提出的"膜区分机理"理论，PL-5代表了一种新作用机制， 其肽二级结构折迭以破坏微生物膜的完整性，以应对抗生素耐药 性危机。凭借其抗耐药性、广谱及高 效性的关键优势，PL-5为治疗多重耐药感染提供了突破性的解决方案。其已连续入选国家十二五、十三 五"重 ...

Group 1 - The core viewpoint of the news is that Shengnuo Bio has shown significant financial growth, with a notable increase in revenue and net profit for the first nine months of 2025 [2] - As of January 29, Shengnuo Bio's stock price decreased by 0.46%, with a trading volume of 89.92 million yuan and a net financing purchase of 3.20 million yuan [1] - The company's financing balance is 464 million yuan, accounting for 7.53% of its market capitalization, which is below the 50th percentile level over the past year, indicating a low financing position [1] Group 2 - Shengnuo Bio's revenue for the period from January to September 2025 reached 520 million yuan, representing a year-on-year growth of 53.96% [2] - The net profit attributable to the parent company for the same period was 127 million yuan, showing a substantial increase of 123.03% year-on-year [2] - The company has distributed a total of 87.14 million yuan in dividends since its A-share listing, with 63.14 million yuan distributed over the past three years [3]

Group 1 - The A-share medical sector weakened on January 26, with AI medical and brain-computer interface concepts leading the decline, as Meien Health dropped by 6% and Weining Health and Sanbo Brain Science fell over 5% [1] - The largest medical ETF in the market (512170) declined by more than 1.6%, losing its half-year line, with real-time transactions exceeding 600 million yuan [1] - Despite the overall decline, the medical ETF (512170) showed high-frequency premiums in the market, indicating active buying interest, with a weekly increase in positions exceeding 813 million yuan [1] Group 2 - CITIC Securities recently published a weekly review of the pharmaceutical industry, indicating that policy impacts will eventually clear, and companies will gradually recover after strategic adjustments, with the medical device sector undergoing dual recovery in valuation and performance [3] - The report suggests increasing allocation to the medical device sector by 2026, with major investment opportunities arising from performance recovery, overseas expansion, brain-computer interfaces, and AI medical technologies, potentially leading to multi-bagger stocks in a tech bull market [3] - The CXO sector is experiencing rapid growth due to advancements in ADC and peptide drugs, with increasing demand for related CXO services, and segments like small nucleic acids and CGT are expected to develop quickly [3] Group 3 - The largest medical ETF (512170) has a fund size of 26.8 billion yuan, making it the largest in the market among medical ETFs [3] - The medical ETF and its linked fund (012323) cover 12 AI medical and brain-computer interface concept stocks, with over 50% weight in medical devices and nearly 25% in CXO [3] - For those interested in Hong Kong stock medical opportunities, the Hong Kong Stock Connect Medical ETF (159137) focuses on medical innovation, gathering core leaders in various pharmaceutical fields, including medical devices, AI medical, CXO, and innovative drugs [3]

Group 1: Company Overview - Shenzhen Hanyu Pharmaceutical Co., Ltd. is a national high-tech enterprise focused on the research, production, and sales of peptide drugs, listed on the Shenzhen Stock Exchange since 2011 (stock code: 300199) [2] - The company has established several national-level laboratories and has received multiple awards, including the National Technology Invention Award (second class) and the Guangdong Provincial Science and Technology Award [3] Group 2: Product Development and Market Strategy - The company is expanding its global presence by accelerating the production capacity of its Wuhan base to meet the rising global demand for GLP-1 raw materials, with core product Liraglutide already approved by the FDA [3] - Future plans include launching 1 to 2 new products annually in the U.S. market and registering existing products in Europe, Latin America, and Asia-Pacific regions [3] - The small nucleic acid field is identified as a second growth curve, with ongoing research targeting major diseases such as hyperlipidemia and diabetes [3] Group 3: CRDMO Business Expansion - The company is building a comprehensive CRDMO service platform, leveraging its expertise in peptide and small nucleic acid production to offer tailored high-quality services [4][6] - A dedicated CRDMO service team is being formed to enhance business capabilities and capitalize on market opportunities [6] Group 4: Domestic Market Strategy - The company is optimizing its supply chain to enhance product competitiveness, ensuring cost efficiency across all production stages [7] - Significant efforts in academic promotion and brand building have established a strong market presence, supported by long-term partnerships with distributors [7] - Future focus areas include increasing academic promotion for existing and upcoming products and maintaining stringent quality control [7] Group 5: Financial Structure and Performance - The company has seen steady growth in operating cash flow, with sales collection management reaching optimal levels [8] - A planned capital increase of 9.68 billion CNY aims to allocate 70% for R&D and capacity upgrades, which is expected to lower the debt-to-asset ratio and improve capital structure [8] - Financial expenses are projected to decrease in 2025 compared to 2024, alleviating financial burdens and supporting profit growth [9] Group 6: Production Capacity Utilization - The Wuhan production facility has maintained operations during recent holidays, indicating strong demand and growth trends [9] - The facility operates on a three-shift system to meet market needs, adhering to a "build and sell" model to align capacity with market demand [9]

Core Viewpoint - Shengnuo Biopharma (688117.SH) is experiencing explosive growth in its performance, with a projected net profit of 152 million to 190 million yuan for 2025, representing a year-on-year increase of 204.42% to 280.53% [1][2] Financial Performance - Shengnuo Biopharma's revenue for 2022 was 396 million yuan, with a net profit of 64.48 million yuan. In 2023, revenue increased to 435 million yuan and net profit to 70.34 million yuan. In 2024, revenue reached 456 million yuan, while net profit slightly declined to 50.02 million yuan, setting the stage for the anticipated growth in 2025 [2] - For 2025, the company expects a significant leap in performance, with net profit projected between 152 million and 190 million yuan, and a non-recurring net profit forecasted between 149 million and 186 million yuan, indicating substantial growth compared to previous years [2] Business Growth Drivers - The core drivers of Shengnuo Biopharma's explosive growth include the rapid expansion of its peptide raw material business and simultaneous market development both domestically and internationally [2] - The company has successfully established a complete industrial chain platform covering peptide raw materials, formulation products, and innovative drug CDMO services over its 20 years of operation [2] Revenue Structure - Shengnuo Biopharma's revenue structure is primarily driven by raw materials and intermediates, with raw materials accounting for 56% of total revenue in the first half of 2025, showing a significant year-on-year growth of 232% [3] - The demand for GLP-1 raw materials has surged globally, driven by the penetration of original drug products in diabetes and obesity treatment, allowing Shengnuo to capitalize on this industry trend [3] Research and Development - The company has steadily increased its R&D investment over the years, with total R&D expenditure reaching 149 million yuan over the past five years, indicating a commitment to enhancing its core technologies and product pipeline [4] - Shengnuo Biopharma has provided peptide innovation drug research and custom production services to over 40 new drug development companies, with several projects at critical clinical trial stages [5] Asset Growth - Shengnuo Biopharma's total assets reached 19.09 billion yuan by the end of the third quarter of 2025, marking a 24.93% year-on-year increase and surpassing the 19 billion yuan milestone [5]

Core Viewpoint - Shengnuo Biotech is expected to achieve significant growth in its peptide API business, driven by capacity expansion and increasing market demand, enhancing its global competitiveness in the peptide pharmaceutical market [1][2][3] Company Performance - Shengnuo Biotech forecasts a net profit attributable to shareholders of approximately 152 million to 190 million yuan for 2025, representing a year-on-year increase of about 102 million to 140 million yuan, or a growth rate of 204.42% to 280.53% [3] - The company's net profit, excluding non-recurring gains and losses, is expected to be around 149 million to 186 million yuan, reflecting a year-on-year increase of approximately 103 million to 140 million yuan, or a growth rate of 226.07% to 307.58% [3] Market Dynamics - Shengnuo Biotech's API products are sold in regions including Europe, the United States, and South Korea, establishing partnerships with well-known pharmaceutical companies such as Fresenius Kabi and others [2] - The global demand for GLP-1 (glucagon-like peptide-1) drugs is high, significantly driving the company's performance [2] - The global peptide drug market is projected to reach 210.8 billion USD by 2030, indicating a strong growth trajectory for the industry [2] Operational Strategy - Shengnuo Biotech is focused on expanding its production capacity while exploring domestic and international markets, which is expected to lead to a steady increase in overall performance [1] - The company has successfully launched several key projects, including a peptide API production line with an annual capacity of 395 kilograms and a formulation industrialization project [1] - The company has developed a differentiated capability through its GMP production capacity system, which helps mitigate risks associated with reliance on single customers [4]

Core Viewpoint - Youcare Pharmaceutical Group Co., Ltd. (悦康药业) has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, aiming to expand its market presence after being listed on the A-share market since December 2020, with a current market capitalization of approximately RMB 10.4 billion [1][16]. Business Overview - Established in 2001, Youcare Pharmaceutical is a biopharmaceutical company with a diverse portfolio of commercially recognized products, focusing on research, development, production, and commercialization of therapies including oligonucleotides, mRNA vaccines, peptides, and innovative traditional Chinese medicine [2][17]. - Key products include Youcare Tong® (Ginkgo biloba extract injection) for managing cerebrovascular and peripheral vascular disorders, Ailisi® (Sildenafil citrate tablets) for treating erectile dysfunction, and other significant products like Liweike® (Omeprazole enteric-coated capsules) and Yuedaning® (Metformin sustained-release tablets) [2][17]. Pipeline and R&D - The company's pipeline includes innovative candidates across various stages, focusing on four core modalities: oligonucleotides, mRNA vaccines, peptides, and innovative traditional Chinese medicine [4][19]. - Notable projects include YKYY013 for chronic hepatitis B, YKYY015 targeting PCSK9 for cardiovascular metabolism, and YKYY029 for hypertension, all of which have received clinical trial approvals in China and the U.S. [4][19]. - In the mRNA vaccine segment, projects YKYY025 and YKYY026 aim to prevent RSV and varicella-zoster virus infections, respectively, with U.S. clinical trial approvals [4][19]. Financial Performance - For the fiscal years ending December 31, 2022, 2023, and 2024, and the first seven months of 2025, Youcare Pharmaceutical reported revenues of RMB 4.52 billion, RMB 4.18 billion, RMB 3.77 billion, and RMB 1.30 billion, respectively, with corresponding net profits of RMB 339 million, RMB 187 million, RMB 121 million, and a loss of RMB 146 million [12][27]. - The revenue breakdown shows significant contributions from cardiovascular, anti-infection, digestive system, and diabetes-related products, with cardiovascular products generating RMB 2.76 billion in 2022 [6][21]. Shareholding Structure - Prior to the Hong Kong listing, the major shareholders include Mr. Yu Weishi and Ms. Ma Guiying, who collectively hold approximately 48.65% of the company, making them the controlling shareholders [7][22]. Board of Directors - The board consists of 11 members, including 7 executive directors led by Mr. Yu Weishi as Chairman and Mr. Yu Fei as General Manager, along with 4 non-executive directors with diverse backgrounds in finance and healthcare [10][25].